Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;128(3):298-303.
doi: 10.1016/j.ymgme.2019.01.020. Epub 2019 Jan 24.

Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management

Manisha Balwani  1
Affiliations
Review

Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management

Manisha Balwani. Mol Genet Metab. 2019 Nov.

Abstract

Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP) are rare, genetic photodermatoses resulting from defects in enzymes of the heme-biosynthetic pathway. EPP results from the partial deficiency of ferrochelatase, and XLP results from gain-of-function mutations in erythroid specific ALAS2. Both disorders result in the accumulation of erythrocyte protoporphyrin, which is released in the plasma and taken up by the liver and vascular endothelium. The accumulated protoporphyrin is activated by sunlight exposure, generating singlet oxygen radical reactions leading to tissue damage and excruciating pain. About 2-5% of patients develop clinically significant liver dysfunction due to protoporphyrin deposition in bile and/or hepatocytes which can advance to cholestatic liver failure requiring transplantation. Clinically these patients present with acute, severe, non-blistering phototoxicity within minutes of sun-exposure. Anemia is seen in about 47% of patients and about 27% of patients will develop abnormal serum aminotransferases. The diagnosis of EPP and XLP is made by detection of markedly increased erythrocyte protoporphyrin levels with a predominance of metal-free protoporphyrin. Genetic testing by sequencing the FECH or ALAS2 gene confirms the diagnosis. Treatment is limited to sun-protection and there are no currently available FDA-approved therapies for these disorders. Afamelanotide, a synthetic analogue of α-melanocyte stimulating hormone was found to increase pain-free sun exposure and improve quality of life in adults with EPP. It has been approved for use in the European Union since 2014 and is not available in the U.S. In addition to the development of effective therapeutics, future studies are needed to establish the role of iron and the risks related to the development of hepatopathy in these patients.

Keywords: Genetics; Heme-biosynthesis; Metabolic; Photodermatosis; Porphyria.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Heme biosynthetic pathway
Figure 2.
Figure 2.
Clinical manifestations: Erythema and edema on the dorsum of hands and forearm seen after acute phototoxic episode.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anderson KE, Sassa S, Bishop DF, and Desnick RJ (2001). Disorders of Heme Biosynthesis: X-Linked Sideroblastic Anemia and the Porphyrias In The Metabolic and Molecurlar Bases of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, and Valle D, eds. (New York, McGraw-Hill: ), pp 2961–3062.
    1. Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, Elder GH, Holme SA, Anstey AV, Parker M, et al. (2008). C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 83, 408–414. - PMC - PubMed
    1. Elder G, Harper P, Badminton M, Sandberg S, and Deybach JC (2013). The incidence of inherited porphyrias in Europe. J Inherit Metab Dis 36, 849–857. - PubMed
    1. Whatley SD, Mason NG, Holme SA, Anstey AV, Elder GH, and Badminton MN (2010). Molecular epidemiology of erythropoietic protoporphyria in the U.K. The British journal of dermatology 162, 642–646. - PubMed
    1. Balwani M, Doheny D, Bishop DF, Nazarenko I, Yasuda M, Dailey HA, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, et al. (2013). Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Molecular medicine 19, 26–35. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources